An Extended Observational Study (P12-707: HOPE III Study) of Follow-up Survey (P12-069: HOPE II Study) of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859)

Trial Profile

An Extended Observational Study (P12-707: HOPE III Study) of Follow-up Survey (P12-069: HOPE II Study) of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859)

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms HOPE-3; HOPE-III; HOPEFUL-3
  • Sponsors Abbott Laboratories; AbbVie; Eisai Co Ltd
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Dec 2014 Status changed from active, no longer recruiting to completed reported by ClinicalTrials.gov
    • 11 Apr 2014 Planned End Date changed from 1 Dec 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top